Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$32.39 +1.7%	$28.55	$23.42 ▼ $62.58	$1.88B	0.77	681,997 shs	760,666 shs
CAPR Capricor Therapeutics	$10.00 -0.9%	$10.21	$3.52 ▼ $23.40	$456.77M	0.85	1.74 million shs	2.09 million shs
CNTA Centessa Pharmaceuticals	$13.14 +0.5%	$12.78	$7.90 ▼ $19.09	$1.76B	1.53	658,782 shs	751,590 shs
SUPN Supernus Pharmaceuticals	$31.79 +0.3%	$31.96	$25.53 ▼ $40.28	$1.78B	0.74	482,798 shs	750,724 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.28%	+7.60%	+9.42%	-10.41%	-16.21%
CAPR Capricor Therapeutics	-5.26%	-7.09%	-19.67%	-34.40%	+80.18%
CNTA Centessa Pharmaceuticals	+0.93%	+3.57%	-4.74%	-15.95%	+62.56%
SUPN Supernus Pharmaceuticals	-1.46%	-1.12%	-2.49%	-1.19%	+19.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.0218 of 5 stars	3.3	1.0	4.2	2.8	0.8	1.9
CAPR Capricor Therapeutics	1.6642 of 5 stars	3.5	1.0	0.0	2.1	0.8	0.6
CNTA Centessa Pharmaceuticals	3.4664 of 5 stars	4.5	1.0	0.0	3.2	3.3	0.6
SUPN Supernus Pharmaceuticals	2.3512 of 5 stars	2.2	1.0	4.1	3.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.00	72.89% Upside
CAPR Capricor Therapeutics	3.00	Buy	$35.50	255.00% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	112.24% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	13.24% Upside

Current Analyst Ratings Breakdown

Latest CAPR, SUPN, AGIO, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/20/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
5/14/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/2/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$74.00 ➝ $71.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/26/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/20/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
3/17/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $77.00
3/7/2025	CNTA Centessa Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$27.00 ➝ $27.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$37.04M	50.65	N/A	N/A	$27.02 per share	1.20
CAPR Capricor Therapeutics	$17.36M	26.31	N/A	N/A	$0.73 per share	13.70
CNTA Centessa Pharmaceuticals	$15M	117.03	N/A	N/A	$2.42 per share	5.43
SUPN Supernus Pharmaceuticals	$668.00M	2.66	$1.46 per share	21.83	$16.87 per share	1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	2.86	N/A	N/A	1,845.92%	-2.51%	-2.26%	8/7/2025 (Estimated)
CAPR Capricor Therapeutics	-$22.29M	-$1.42	N/A	N/A	N/A	-146.86%	-112.95%	-57.00%	8/6/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.81	N/A	N/A	N/A	N/A	-52.13%	-38.01%	8/12/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$1.32M	$1.11	29.71	22.08	N/A	9.16%	7.79%	5.67%	8/5/2025 (Estimated)

Latest CAPR, SUPN, AGIO, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A
3/19/2025	Q4 2024	CAPR Capricor Therapeutics	-$0.31	-$0.16	+$0.15	-$0.16	$9.87 million	$11.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
CAPR Capricor Therapeutics	N/A	4.19	4.19
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
SUPN Supernus Pharmaceuticals	N/A	2.20	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
CAPR Capricor Therapeutics	21.68%
CNTA Centessa Pharmaceuticals	82.01%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
CAPR Capricor Therapeutics	10.50%
CNTA Centessa Pharmaceuticals	7.09%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	54.47 million	Optionable
CAPR Capricor Therapeutics	N/A	45.68 million	40.01 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.60 million	116.56 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	50.08 million	Optionable

CAPR, SUPN, AGIO, and CNTA Headlines

Recent News About These Companies

Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree

May 29 at 9:14 AM | quiverquant.com

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 29 at 8:30 AM | globenewswire.com

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 28 at 4:05 PM | globenewswire.com

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28 at 4:05 PM | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), 908 Devices (MASS) and Supernus Pharmaceuticals (SUPN)

May 24, 2025 | theglobeandmail.com

Woodline Partners LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 24, 2025 | marketbeat.com

Point72 Asset Management L.P. Buys Shares of 26,828 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 24, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Deutsche Bank AG

May 22, 2025 | marketbeat.com

Supernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHD

May 20, 2025 | quiverquant.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Systematic Financial Management LP

May 20, 2025 | marketbeat.com

Captrust Financial Advisors Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 20, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Ameriprise Financial Inc.

May 19, 2025 | marketbeat.com

Jefferies Financial Group Inc. Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 18, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Polar Capital Holdings Plc

May 17, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Has $19.73 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 15, 2025 | marketbeat.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

May 14, 2025 | zacks.com

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 103,501 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 14, 2025 | marketbeat.com

Centiva Capital LP Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 14, 2025 | marketbeat.com

BNP Paribas Financial Markets Buys 208,552 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 14, 2025 | marketbeat.com

Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business

May 13, 2025 | finance.yahoo.com

Comerica Bank Buys 15,585 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

May 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, SUPN, AGIO, and CNTA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$32.39 +0.55 (+1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$32.10 -0.30 (-0.91%)

As of 06:00 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$10.00 -0.09 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$10.15 +0.15 (+1.55%)

As of 06:52 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.14 +0.07 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$13.48 +0.33 (+2.55%)

As of 05:51 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Supernus Pharmaceuticals NASDAQ:SUPN

$31.79 +0.11 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$31.70 -0.09 (-0.28%)

As of 04:37 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time